Biosimilars Industry Hopes For Jump-Start From User Fees
The new biosimilars user fee program, signed into law last week, focuses on funding early meetings between sponsors and U.S. Food and Drug Administration reviewers, meetings that experts say will be...To view the full article, register now.
Already a subscriber? Click here to view full article